Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KRYSNASDAQ:LNTHNASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKRYSKrystal Biotech$141.35+1.7%$139.09$122.80▼$219.34$4.02B0.67286,940 shs209,978 shsLNTHLantheus$79.62+0.3%$83.51$73.11▼$126.89$5.49B0.121.02 million shs912,617 shsSRPTSarepta Therapeutics$18.19+2.7%$37.06$16.88▼$155.95$1.74B0.452.17 million shs4.62 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKRYSKrystal Biotech+1.68%-0.81%+12.76%-20.65%-20.42%LNTHLantheus+0.25%-1.15%+3.23%-18.09%+1.43%SRPTSarepta Therapeutics+2.71%+4.18%-51.80%-68.96%-88.20%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKRYSKrystal Biotech4.5544 of 5 stars3.51.00.04.72.52.51.9LNTHLantheus4.457 of 5 stars3.51.00.04.22.22.51.9SRPTSarepta Therapeutics4.7344 of 5 stars4.22.00.04.22.31.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKRYSKrystal Biotech 3.00Buy$211.1349.36% UpsideLNTHLantheus 3.00Buy$130.5063.90% UpsideSRPTSarepta Therapeutics 2.44Hold$60.88234.66% UpsideCurrent Analyst Ratings BreakdownLatest SRPT, KRYS, and LNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025SRPTSarepta TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Sell6/24/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$240.006/23/2025LNTHLantheusB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$122.00 ➝ $109.006/20/2025SRPTSarepta TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$123.00 ➝ $45.006/20/2025SRPTSarepta TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform6/18/2025SRPTSarepta TherapeuticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$85.00 ➝ $40.006/18/2025SRPTSarepta TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$24.006/17/2025SRPTSarepta TherapeuticsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$50.00 ➝ $25.006/17/2025SRPTSarepta TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$29.006/17/2025SRPTSarepta TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$60.00 ➝ $30.006/17/2025SRPTSarepta TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$100.00 ➝ $75.00(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKRYSKrystal Biotech$290.52M14.06$4.71 per share29.98$32.90 per share4.30LNTHLantheus$1.53B3.59$7.12 per share11.19$15.65 per share5.09SRPTSarepta Therapeutics$1.90B0.94$2.50 per share7.27$15.99 per share1.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKRYSKrystal Biotech$89.16M$4.1633.9814.02N/A37.17%14.64%13.28%8/4/2025 (Estimated)LNTHLantheus$312.44M$3.5222.6212.62N/A16.55%36.99%20.55%7/30/2025 (Estimated)SRPTSarepta Therapeutics$235.24M-$2.69N/A1.66N/A-11.12%-14.88%-5.12%8/6/2025 (Estimated)Latest SRPT, KRYS, and LNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q2 2025LNTHLantheus$1.65N/AN/AN/A$389.69 millionN/A5/7/2025Q1 2025LNTHLantheus$1.64$1.53-$0.11$1.02$377.37 million$372.76 million5/6/2025Q1 2025KRYSKrystal Biotech$1.38$1.20-$0.18$1.20$98.66 million$88.18 million5/6/2025Q1 2025SRPTSarepta Therapeutics$2.20-$3.42-$5.62-$4.60$685.75 million$744.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKRYSKrystal BiotechN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKRYSKrystal BiotechN/A9.659.27LNTHLantheus0.495.745.46SRPTSarepta Therapeutics1.004.022.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKRYSKrystal Biotech86.29%LNTHLantheus99.06%SRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipKRYSKrystal Biotech13.70%LNTHLantheus1.50%SRPTSarepta Therapeutics7.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKRYSKrystal Biotech21028.90 million24.94 millionOptionableLNTHLantheus70069.19 million68.15 millionOptionableSRPTSarepta Therapeutics1,37298.28 million90.71 millionOptionableSRPT, KRYS, and LNTH HeadlinesRecent News About These CompaniesShareholders of Sarepta Therapeutics, Inc. Should Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights – SRPTJuly 2 at 3:58 PM | globenewswire.comSRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud LawsuitJuly 2 at 3:38 PM | prnewswire.comINVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)July 2 at 12:51 PM | globenewswire.comDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta TherapeuticsJuly 2 at 11:45 AM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPTJuly 2 at 10:00 AM | prnewswire.comSRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPTJuly 2 at 9:24 AM | prnewswire.comPeregrine Capital Management LLC Purchases 15,070 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)July 2 at 5:25 AM | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Sets New 12-Month Low - Here's What HappenedJuly 2 at 4:49 AM | marketbeat.comSRPT INVESTOR NOTICE: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJuly 1 at 4:21 PM | prnewswire.comSRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJuly 1 at 4:00 PM | prnewswire.comROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPTJuly 1 at 1:30 PM | globenewswire.comSAREPTA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the FirmJune 30 at 9:00 PM | globenewswire.comShareholder Alert: Robbins LLP Informs Investors of the Sarepta Therapeutics, Inc. Class ActionJune 30 at 7:28 PM | globenewswire.comSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 30 at 6:26 PM | businesswire.comSRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmJune 30 at 4:17 PM | prnewswire.comROSEN, SKILLED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPTJune 30 at 1:22 PM | markets.businessinsider.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta TherapeuticsJune 30 at 1:22 PM | markets.businessinsider.comSAREPTA THERAPEUTICS, INC. (NASDAQ: SRPT) INVESTOR ALERT: Investors With Large Losses in Sarepta Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their RightsJune 30 at 12:30 PM | globenewswire.comINVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. (SRPT) Investors with Substantial Losses Have Opportunity to Lead the Sarepta Class Action LawsuitJune 30 at 6:00 AM | globenewswire.comSarepta Investor Sues After Duchenne Gene Therapy Patient DeathsJune 29, 2025 | news.bloomberglaw.comNSRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, ...June 29, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSRPT, KRYS, and LNTH Company DescriptionsKrystal Biotech NASDAQ:KRYS$141.35 +2.34 (+1.68%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$141.55 +0.20 (+0.14%) As of 07/2/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Lantheus NASDAQ:LNTH$79.62 +0.20 (+0.25%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$79.22 -0.40 (-0.50%) As of 07/2/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Sarepta Therapeutics NASDAQ:SRPT$18.19 +0.48 (+2.71%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$18.34 +0.15 (+0.85%) As of 05:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Jefferies Raises Broadcom Price Target to $315: 19% Upside Ahead Dan Ives’ Bold $5 Trillion Forecast for Microsoft Stock 3 Utility Stocks That Combine Income and Stability 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
